FLT3 and acute myeloid leukemia: Among AML patients, three patients did not have identified molecular markers for minimal residual disease (MRD) monitoring, one had NPM1 and FLT3-ITD mutations (patient number 11), one had RUNX1-RUNX1T1 gene fusion (patient number 14), and one had BCR-ABL1 gene fusion (patient number 12, Table 2).